These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 11285774

  • 1. [Value of positron emission tomography in treatment of lymphoma patients].
    Kuwert T.
    Strahlenther Onkol; 2001 Mar; 177(3):160-1. PubMed ID: 11285774
    [No Abstract] [Full Text] [Related]

  • 2. Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma.
    Cremerius U, Fabry U, Neuerburg J, Zimny M, Osieka R, Buell U.
    Nucl Med Commun; 1998 Nov; 19(11):1055-63. PubMed ID: 9861622
    [Abstract] [Full Text] [Related]

  • 3. FDG PET in the management of lymphoma: a clinical perspective.
    Hoskin PJ.
    Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):449-51. PubMed ID: 11914880
    [No Abstract] [Full Text] [Related]

  • 4. Fluorine-18 fluorodeoxyglucose positron emission tomography for lymphoma: incorporating new technology into clinical care.
    Kaplan LD.
    Am J Med; 2002 Mar; 112(4):320-1. PubMed ID: 11893374
    [No Abstract] [Full Text] [Related]

  • 5. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
    Becherer A, Mitterbauer M, Jaeger U, Kalhs P, Greinix HT, Karanikas G, Pötzi C, Raderer M, Dudczak R, Kletter K.
    Leukemia; 2002 Feb; 16(2):260-7. PubMed ID: 11840293
    [Abstract] [Full Text] [Related]

  • 6. [Positron emission tomography (PET) in diagnosis and therapy planning of malignant lymphoma].
    Dimitrakopoulou-Strauss A, Strauss LG, Goldschmidt H, Hegenbart U, Irngartinger G, Oberdorfer F, van Kaick G.
    Radiologe; 1997 Jan; 37(1):74-80. PubMed ID: 9157479
    [Abstract] [Full Text] [Related]

  • 7. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.
    Specht L.
    Semin Radiat Oncol; 2007 Jul; 17(3):190-7. PubMed ID: 17591566
    [Abstract] [Full Text] [Related]

  • 8. Value of positron emission tomography in diagnosing subcutaneous panniculitis-like T-cell lymphoma.
    Bennani-Baiti B, Yadav S, Flynt L, Bennani-Baiti N.
    J Clin Oncol; 2015 Apr 01; 33(10):1216-7. PubMed ID: 25691676
    [No Abstract] [Full Text] [Related]

  • 9. [Standards, Options and Recommendations for the use of PET-FDG in cancerology. Results in the treatment of Hodgkin's disease and malignant non-Hodgkin's lymphoma].
    Bourguet P, Groupe de Travail SOR.
    Bull Cancer; 2003 Feb 01; 90 Spec No():S88-95. PubMed ID: 12739340
    [No Abstract] [Full Text] [Related]

  • 10. Positron emission tomography in the management of lymphomas: a summary.
    O'Doherty MJ, Hoskin PJ.
    Eur J Nucl Med Mol Imaging; 2003 Jun 01; 30 Suppl 1():S128-30. PubMed ID: 12692689
    [No Abstract] [Full Text] [Related]

  • 11. Commentary: PET poised to alter the current paradigm for response assessment of non-Hodgkin's lymphoma.
    Guermazi A, Juweid ME.
    Br J Radiol; 2006 May 01; 79(941):365-7. PubMed ID: 16632614
    [No Abstract] [Full Text] [Related]

  • 12. New staging and response criteria for non-Hodgkin lymphoma and Hodgkin lymphoma.
    Cheson BD.
    Radiol Clin North Am; 2008 Mar 01; 46(2):213-23, vii. PubMed ID: 18619377
    [Abstract] [Full Text] [Related]

  • 13. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma.
    de Wit M, Bumann D, Beyer W, Herbst K, Clausen M, Hossfeld DK.
    Ann Oncol; 1997 Mar 01; 8 Suppl 1():57-60. PubMed ID: 9187431
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of treatment response in patients with lymphoma using [18F]FDG-PET: differences between non-Hodgkin's lymphoma and Hodgkin's disease.
    Spaepen K, Mortelmans L.
    Q J Nucl Med; 2001 Sep 01; 45(3):269-73. PubMed ID: 11788819
    [Abstract] [Full Text] [Related]

  • 15. The role of PET imaging in lymphoma.
    Burton C, Ell P, Linch D.
    Br J Haematol; 2004 Sep 01; 126(6):772-84. PubMed ID: 15352980
    [Abstract] [Full Text] [Related]

  • 16. Importance of F18-fluorodeoxy-D-2-glucose positron emission tomography (FDG-PET) for staging and therapy control of Hodgkin's lymphoma in childhood and adolescence - consequences for the GPOH-HD 2003 protocol.
    Körholz D, Kluge R, Wickmann L, Hirsch W, Lüders H, Lotz I, Dannenberg C, Hasenclever D, Dörffel W, Sabri O.
    Onkologie; 2003 Oct 01; 26(5):489-93. PubMed ID: 14605468
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Do not abandon the bone marrow biopsy yet in diffuse large B-cell lymphoma.
    Adams HJ, Kwee TC.
    J Clin Oncol; 2015 Apr 01; 33(10):1217. PubMed ID: 25691675
    [No Abstract] [Full Text] [Related]

  • 19. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma.
    Kostakoglu L, Leonard JP, Kuji I, Coleman M, Vallabhajosula S, Goldsmith SJ.
    Cancer; 2002 Feb 15; 94(4):879-88. PubMed ID: 11920454
    [Abstract] [Full Text] [Related]

  • 20. Positron emission tomography with [(18)F]FDG for therapy response monitoring in lymphoma patients.
    Spaepen K, Stroobants S, Verhoef G, Mortelmans L.
    Eur J Nucl Med Mol Imaging; 2003 Jun 15; 30 Suppl 1():S97-105. PubMed ID: 12709831
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.